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Abstract
Glycopeptides are still the gold standard to treat MRSA (Methicillin Resistant Staphylococcus aureus) infections, but their
widespread use has led to vancomycin-reduced susceptibility [heterogeneous Vancomycin-Intermediate-Staphylococcus
aureus (hVISA) and Vancomycin-Intermediate-Staphylococcus aureus (VISA)], in which different genetic loci (regulatory,
autolytic, cell-wall turnover and cell-envelope positive charge genes) are involved. In addition, reduced susceptibility to
vancomycin can influence the development of resistance to daptomycin. Although the phenotypic and molecular changes
of hVISA/VISA have been the focus of different papers, the molecular mechanisms responsible for these different
phenotypes and for the vancomycin and daptomycin cross-resistance are not clearly understood. The aim of our study was
to investigate, by real time RT-PCR, the relative quantitative expression of genes involved in autolysis (atl-lytM), cell-wall
turnover (sceD), membrane charges (mprF-dltA) and regulatory mechanisms (agr-locus-graRS-walKR), in hVISA and VISA
cultured with or without vancomycin and daptomycin, in order to better understand the molecular basis of vancomycin-
reduced susceptibility and the modulating activity of vancomycin and daptomycin on the expression of genes implicated in
their reduced susceptibility mechanisms. Our results show that hVISA and VISA present common features that distinguish
them from Vancomycin-Susceptible Staphylococcus aureus (VSSA), responsible for the intermediate glycopeptide resistance
i.e. an increased cell-wall turnover, an increased positive cell-wall charge responsible for a repulsion mechanism towards
vancomycin and daptomycin, and reduced agr-functionality. Indeed, VISA emerges from hVISA when VISA acquires a
reduced autolysis caused by a down-regulation of autolysin genes, atl/lytM, and a reduction of the net negative cell-
envelope charge via dltA over-expression. Vancomycin and daptomycin, acting in a similar manner in hVISA and VISA, can
influence their cross-resistance mechanisms promoting VISA behavior in hVISA and enhancing the cell-wall pathways
responsible for the intermediate vancomycin resistance in VISA. Daptomycin can also induce a charge repulsion mechanism
both in hVISA and VISA increasing the activity of the mprF.
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Introduction
Emerging resistance to glycopeptides in Methicillin-Resistant
Staphylococcus aureus (MRSA) poses a great threat to antimicrobial
chemotherapy worldwide. Together with the recent discovery, in
2002, of the first clinical isolate of fully Vancomycin-Resistant
S.aureus (VRSA) with VAN MIC .128 mg/L [1], numerous other
isolates of homogeneous Vancomycin-Intermediate Staphylococcus
aureus (VISA) or heterogeneous Vancomycin-Intermediate Staph-
ylococcus aureus (hVISA) have been isolated worldwide. In these
strains, this reduced susceptibility has been attributed to various
cell-wall abnormalities, evolving in a multi-step fashion. These
abnormalities include accumulation of D-Ala-D-Ala targets due to
decreased cross-linking of peptidoglycan [2], the increased
proportion of non-amidated muropeptides [3], and decreased
alanylation of teichoic acids [4].
VISA does not emerge from vancomycin-susceptible MRSA but
from hVISA, as was previously demonstrated: hVISA spontane-
ously produces VISA cells within its cell population at a frequency
of 10
26 or above [5] that is the same frequency of hVISA onset
from a susceptible background [6].
Recent publications have added to the knowledge of the
complex changes taking place in Staphylococci evolving towards
the reduced glycopeptide susceptibility phenomenon. A reduced
content of Lysyl-phosphatidylglycerol (LPG), synthesized by fmtC
(also named mprF) encoded protein, has recently been demon-
strated affecting some cationic antimicrobial agents including
vancomycin (VAN), but also the Ca
2+-d a p t o m y c i n( D A P )[ 7 ] .I n
addition, a possible role of the autolytic enzymes has also been
suggested, among which the major autolysin atl [8], the
peptidoglycan hydrolase lytM [9], and the transglycolase sceD
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mediators of cell division, autolysis and peptidoglycan turnover.
Moreover, different regulatory loci have been found to be
involved in vancomycin intermediate resistance such as agr-locus
(accessory gene regulator locus) encoding d-hemolysin and also
considered as its functionality indicator; GraRS and WalKR, both
encoding Two-Component Regulatory Systems ‘‘TCRSs’’, in-
volvedintheregulationofmprF/dltAa n datl/lytM/sceD,respectively
[11–20].
GraRS has been involved in the VISA phenotype, because these
lead to increased autolytic rates and a more negative net surface
charge, which increase the sensitivity to cationic antimicrobial
peptides [15].
Recently, Dubrac et al. emphasized the importance of the
walKR system in cell-wall metabolism in S.aureus [19]. Moreover,
Jansen et al. reported that walKR was highly up-regulated due to
an insertion mutation in the walKR promoter in a VISA clinical
isolate, suggesting that the increment of vancomycin resistance was
mediated by activation of this system [17]. On the contrary, in a
recent paper, Hiramatsu et al. reported a deletion mutation in
walKR [deletion of 3 nucleotides (CAA) from the position 1111 to
1113] and a truncating mutation in a proteoliytic regulatory gene,
clpC, responsible for the raised vancomycin resistance in a
laboratory derivate strain, but they did not find any significant
changes in the expression of walKR in any of the resistant mutants
studied. Thus, the cause of raised resistance due to the walKR
mutation still remains unknown [21]. Moreover, Delaune et al.
recently reported on the effect of walKR on cell morphology,
showing that walKR depletion could raise the cell-wall thickness of
S.aureus [20], but this regulatory pathway toward cell-wall
thickening remains to be studied.
It has been postulated that reduced susceptibility to VAN can
influence the susceptibility to DAP by the thickness of the VISA
cell-wall [22]. Furthermore, some of the above mentioned loci,
such as mprF and dlt-operon, have also been involved in DAP
resistance mechanisms of S.aureus [23–25].
With all this in mind, and using a real time RT-PCR approach,
we investigated the relative quantitative expression of some genes
involved in autolysis, cell-wall turnover, membrane charges and
global regulation, on a sample of hVISA and VISA isolates, in
order to define the possible modulating activity of VAN and DAP
on the expression of the above mentioned genes involved both in
the mechanisms of glycopeptide reduced susceptibility and
daptomycin resistance.
Results
Phenotype and molecular characteristics of the strains
The strains showed a range of resistance to glycopeptides from
fully susceptible (NRS149) to hetero-resistant (Mu3 and CZ1,
SS33, 004/210 with PAP/AUC ratio of 1.06, 1.07 and 1.22
respectively) to homogenous intermediate Mu50, both with Macro
E-test (MET) and PAP/AUC analyses (gold standard method). All
isolates were susceptible to daptomycin with the only exception of
Mu50 that shows a daptomycin MIC value of 2 mg/L considered
as borderline phenotype. All strains homogeneously belonged to
agr-group II and to Clonal Complex 5 (CC5); in particular, three
of them were Sequence Type 5 (ST) and the three clinical isolates
CZ1, SS33 and 004/210 belonged to the well-known nosocomial
ST228. MRSA strains possessed the Staphylococcal Cassette
Chromosome mec I (SCCmec I) and II type (Table 1).
Total autolysis ratio and d-hemolysin production
Table 2 shows the autolysis ratio, read as an optical density
(O.D.) value obtained in drug-free medium cultured strains,
demonstrating the greatest total Triton X-100 autolysis (75–76%)
in hVISA with respect to the susceptible strain. A lower Triton X-
100 autolysis was found in Mu50 and in the clinical strain 004/210
(49 and 60%, respectively).
Our results evidence a gradient of reduction of the d-hemolysin
production from NRS149 to Mu50. In particular, Mu50 and 004/
210 lacked the d-hemolysis activity whereas NRS149 presented a
large zone of hemolysis. hVISA (Mu3, CZ1, and SS33) exhibited,
instead, a low d-hemolysis activity (Figure 1).
graR and walK mutations
Sequence analysis of graR excluded the presence of the
mutation, changing the 1197th Asn in Ser, related to vancomycin
resistance in CZ1, SS33, and 004/210. walK sequencing revealed
the absence of the truncating mutation of 3 nucleotides (CAA)
from the position 1111 to 1113 in all tested strains.
Table 1. Strains included in the study.
Strain Origin Source
Oxacillin
Resistance
Glycopeptide
phenotype
MIC
(mg/L)
Macro
ETest
(mg/L)
MLST/sscmec
characterization agr-group
VTD VT
NRS149 NARSA Nares of nurse MSSA VSSA 1 0.5 0.5 1 0.5 ST5 II
Mu3 NARSA Purulent sputum MRSA hVISA 0.5 8 1 6 24 ST-5
scc-mecII
II
Mu50 NARSA Wound Skin/Soft
tissue
MRSA VISA 8 16 2 12 12 ST-5
scc-mecII
II
CZ1 Clinical Isolate Air pipe MRSA hVISA 1 0.5 0.5 4 16 ST-228
scc-mecI
II
SS33 Clinical Isolate Blood MRSA hVISA 0.5 0.5 0.5 4 16 ST-228
scc-mecI
II
004/210 Clinical Isolate Abscess/pus MRSA hVISA 1 0.5 0.5 6 12 ST-228
scc-mecI
II
Legend: V=Vancomycin, T=Teicoplanin, D=Daptomycin, S=Susceptible, R=Resistant.
doi:10.1371/journal.pone.0029573.t001
hVISA/VISA: VAN and DAP Role on Gene-Expression
PLoS ONE | www.plosone.org 2 January 2012 | Volume 7 | Issue 1 | e29573Relative quantitative expression of some autolytic, cell-
wall charge and virulence regulator genes in drug-free
conditions
Figure 2A, 2B and Table S1 show the relative quantitative
expression of autolytic, cell-wall charge and virulence regulator
genes considered in the study, as a ratio of transcripts of hVISA
and VISA versus VSSA, in drug-free conditions.
The virulence regulator, rnaIII, showed significantly decreased
fold changes in Mu3, CZ1, SS33 and 004/210, and more so in
Mu50 with respect to NRS149. This behavior was perfectly
comparable to the phenotypes observed in hemolysis assays
(Table 2).
No significant differences were observed, in all tested isolates, in
the expression of the regulator graRS versus NRS149 (data not
shown). Furthermore, walK was significantly up-regulated only in
Mu3-CZ1-SS33 versus NRS149. On the contrary, no significant
walK expression changes were found in Mu50 and 004/210 with
respect to NRS149.
Our experiments of atl expression highlighted a down-
regulation of this gene in Mu50 with respect to NRS149, whereas
statistically significant differences were not detected between the
remaining strains. The relationship between the lytM transcript
amounts was similar to the atl one, with the exception of 004/210
showing a down-regulation in the same way as in Mu50. The
analysis of sceD transcription showed an up-regulation in all
studied strains with respect to NRS149, and a higher expression in
Mu3 and Mu50.
With regard to the two genes involved in cell-wall charge, mprF
expression showed an up-regulation of its transcription in Mu3,
CZ1, SS33 and 004/210, whereas Mu50 presented no significant
changes with respect to NRS149. dltA expression presented an up-
regulation of its transcription only in Mu50 with respect to
NRS149.
Relative quantitative expression of some autolytic, cell-
wall charge and virulence regulator genes with VAN and
DAP
The picture of relative quantitative expression in the presence of
sub-inhibitory concentrations of VAN and DAP showed the
influence of these antimicrobials on the expression of autolytic,
cell-wall charge, and regulatory genes in NRS149, Mu3 and Mu50
(Figure 3, Table S2).
No significant differences in rnaIII and graRS expression were
observed in the presence of VAN and DAP in the growth medium
in all of the studied S.aureus strains (data not shown). Only walK
had a significant down-regulation in Mu50 with both antimicro-
bials (Table S2).
In the presence of VAN and DAP, Mu50 and Mu3 showed a
very low transcription level of the atl gene with respect to the drug-
free conditions. Moreover, atl expression ratio between the two
strains was lower in Mu50 than Mu3 both with VAN and DAP.
With both antimicrobials, the amount of lytM transcripts was
similar to the atl ones both in Mu3 and Mu50, whilst no significant
lytM expression changes were observed in Mu50 with VAN versus
Mu50 in drug-free conditions. Despite the different activity on the
lytM expression of the two antimicrobials on Mu3 and Mu50, a
similar ratio of lytM transcripts was found between these isolates in
the presence of VAN and DAP.
A strong sceD down-regulation versus drug-free conditions was
induced by DAP, and more so by VAN, in Mu3 and Mu50.
Furthermore, the sceD transcript ratio showed a down-regulation
in Mu3 both with VAN and DAP with respect to Mu50.
DAP determined an increase of the mprF transcripts in Mu3 and
more so in Mu50. In the presence of VAN, instead, a strong down-
Table 2. d-hemolysis, Autolysis Ratio, Percentage of Triton X-100 autolysis vs. VSSA.
Strain
d-hemolysin
production*
Autolysis Ratio
(means ± SD)**
Percentage of Triton X-100 autolysis vs.
VSSA
NRS149 ++ 2.6860.05 2
Mu3 +/2 2.0460.07 76%
Mu50 2 1.3360.06 49%
CZ1 +/2 2.0060.04 76%
SS33 +/2 2.0260.07 75%
004/210 2 1.6260.07 60%
Legend:
*(++) large d-hemolysis zone; (2/+)l o wd-hemolysis zone; (2)n od-hemolysis zone.
**measured as the T0/T5 O.D. ratio 6 SD (Standard Deviation).
doi:10.1371/journal.pone.0029573.t002
Figure 1. d-hemolysis assay of prototype microrganisms. A)
NRS149 (VSSA); B) Mu3 (hVISA); C) Mu50 (VISA).
doi:10.1371/journal.pone.0029573.g001
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the two antimicrobials, no significant differences in the mprF
expression were found comparing the two strains with DAP and
VAN.
dltA down-regulation was shown by VAN and DAP in both
Mu3 and Mu50 with respect to strains grown in drug-free
conditions, with the only exception of Mu3 in the presence of
VAN in which no significant changes were found with respect to
drug-free conditions. A higher dltA transcription was always found
in Mu50 than Mu3 in the presence of DAP. The addition of VAN
in the growth medium showed no significant differences in the dltA
transcription level between Mu3 and Mu50.
In vancomycin susceptible strain NRS149, the analysis of
quantitative transcription profile of autolysin, cell wall turnover
and charge genes showed that VAN down-regulated lytM and
dltA, whereas only atl was up-regulated. No significant changes
with respect to drug-free conditions were found in the amount of
sceD and mprF transcripts. Furthermore, DAP significantly down-
regulated atl, sceD, and dltA, but no significant changes were found
for the other tested genes (Figure 3, Table S2).
Figure 2. Transcript analysis in drug-free conditions. (A) Relative quantitative expression of the rnaIII and walK regulator genes and (B) of
some autolytic (atl, lytM), cell-wall turnover (sceD) and cell envelope charge genes (mprF, dltA) in hVISA and VISA. Statistically significant difference
between sample vs. VSSA, p,0.05, are indicated with *.
doi:10.1371/journal.pone.0029573.g002
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Glycopeptide reduced susceptibility is a multifactorial event due
to several biological factors including thickened cell-wall, reduced
cell-wall turnover and autolysis, and increased cell-wall synthesis
that lead to reduced vancomycin access to its active site, the
division septum [3,12]. Although the phenotypic changes of
hVISA/VISA strains have been the main topic of numerous
papers that have attempted to clarify this behavior, molecular
mechanisms responsible for the different phenotypes are still not
clearly understood.
Two different pathways can be involved in cell-wall thickening
i.e.: i) the production of an excess amount of peptidoglycan or; ii)
reduced peptidoglycan turnover and cell lysis [22]. For these
reasons, we studied the expression levels of different enzymes,
selected on the basis of previous proteomic and expression studies,
involved in cell-wall expansion, turnover, growth, and cell
separation, cell-envelope charge and regulatory mechanisms, in
particular: i) agr-locus, WalKR, and GraRS; ii) the atl gene,
encoding a bi-functional enzyme, with an amidase and a
glucosaminidase domain that represents the most predominant
peptidoglycan hydrolase of S.aureus; iii) the lytM gene, encoding a
Gly-Gly endopeptidase; and iv) the sceD gene (SAV 2095 sceD-like
gene) encoding a lytic transglycosylase [11–20,26–33].
A loss of agr-functionality in S.aureus has also been linked with
glycopeptide reduced susceptibility [13]. We observed progressive
attenuated hemolytic properties between hVISA and VISA when
plated on sheep blood agar plates. In particular, hVISA produced
a low amount of delta-hemolysin at 24 h, whereas VISA did not
produce it at all, as shown by the absence of hemolysis at the
interface with RN4220. Since hld (the gene encoding delta-
hemolysin) and its promoter are intact in Mu3 and Mu50, the lack
of delta-hemolysin expression was most likely due to the loss of agr
functionality in agreement with previously published data [14,34].
Our studies on hld expression indicate a progressive down-
regulation of this gene with respect to VSSA, both in h-VISA and
VISA, correlating completely with the hemolytic phenotype
observed [12]. It is also important to underline that these strains
can be less toxigenic than VSSA, since they did not activate the
regulatory mechanisms leading to the production of the main toxin
genes, and more in general, of different virulence determinants
such as spa, encoding protein A [12]. Therefore, our findings
provide experimental support for the use of the d-hemolytic assay
as a biomarker to easily and rapidly identify isolates with reduced
vancomycin susceptibility as recently presented at ECCMID 2011
Congress, Milan, by our group.
An increased sensitivity to cationic antimicrobial peptides, such
as vancomycin and daptomycin, has been attributed to mutations
in graRS that lead to increased autolytic rates and a more negative
net surface charge [15]. Our studies on graRS, in contrast with
results previously published [15,16], and based on statistically
significant data found neither the presence of graRS drug-
resistance related mutations nor a significant up-regulation of
graRS, involved in the regulation of mprF and dltA expression, in all
the studied isolates and in all conditions (drug-free and in the
presence of VAN and DAP) (data not shown).
Regarding the presence of resistance-related mutations and the
WalKR expression, we found no deletion of 3 nucleotides (CAA)
Figure 3. Transcript analysis in presence of vancomycin and daptomycin. Relative quantitative expression of some autolytic (atl, lytM), cell-
wall turnover (sceD) and cell envelope genes (mprF, dltA) of VSSA, hVISA and VISA with VAN (V) and Ca
2+-DAP (D) vs drug-free conditions (FREE).
Statistically significant difference between sample vs. free drug conditions, p,0.05, are indicated with *.
doi:10.1371/journal.pone.0029573.g003
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in drug-free conditions, we found an increased walK expression in
hVISA, relating to a high Triton X-100 autolysis and an atl/lytM
expression profile similar to VSSA. On the contrary, a low Triton
X-100 autolysis and a decrement of atl/lytM transcription,
correlating with no increment of walK transcripts, was found in
Mu50. Thus, we consider that, in VISA, the reduction of the main
autolysin activity can be related to a low walK expression. In
addition, DAP and VAN can enhance these molecular traits of the
VISA phenotype.
As concerns the autolytic activity, our data show that, in drug-
free medium, the VISA strain (Mu50) is constitutively character-
ized by a low Triton X-100 autolysis ratio, a reduced expression of
atl and lytM with respect to hVISA and, obviously, VSSA,
suggesting that a reduction of atl and lytM expression can
contribute to the characteristic low autolysis ratio that plays a
key role in the VISA mechanism of resistance. On the contrary, in
hVISA, our experiments showed a Triton X-100 autolysis ratio
and atl and lytM expression levels similar to those of VSSA,
suggesting that atl- and lytM-mediated cell lysis is not a crucial
point in the mechanism of heterogeneous vancomycin reduced
susceptibility. Our analysis of gene expression, on drug-induced
growth, leads us to important new considerations. These
antimicrobials exhibit the same modulating activity on the
expression of atl both in Mu3 and Mu50, down-regulating both
strains but with a stronger effect on Mu3, shifting Mu3 towards a
behavior that is more similar to Mu50. This consistent reduction
of atl expression was ‘‘drug-induced’’ by both VAN and DAP in
Mu3, and ‘‘drug-enhanced’’ in Mu50. Similar considerations can
be made for the lytM down-regulation that would result in a
‘‘drug-induced effect’’ by both antimicrobials in Mu3. Further-
more, we evidenced that VAN and DAP can determine in
NRS149 a down-regulation of lytM and atl respectively, highlight-
ing that these antimicrobials can also induce in VSSA the
molecular traits leading towards a vancomycin-reduced susceptible
phenotype. Thus, VAN and DAP induce, also in VSSA, the
expression and consequently the synthesis of enzymes involved in
the cell-wall architecture, responsible for the mechanisms of
glycopeptide reduced susceptibility.
An abundance of sceD transcripts is a distinctive feature both in
hVISAandVISA,grownindrug-freeconditions,correlatingwithan
enhanced cell-wall turnover and the presence of an altered cell-wall
structure, in agreement with results obtained by other authors [35].
VAN and DAP also showed a comparable activity on sceD
expression. VAN and DAP addition strongly down-regulated sceD
transcription in Mu3 and in Mu50, in contrast with other findings
[10]. Thus, sceD over-expression is a constitutive feature of the
hVISA and VISA phenotype.
Genes involved in the net positive charge of the cell-wall and
cell membrane i.e. mprF and dltA, were also identified as genetic
determinants that mediate both vancomycin reduced susceptibility
and daptomycin resistance in S.aureus. mprF is involved in: i) Lys-
PG synthesis (a major component of the cell-wall), changing the
content of the cell-wall by reducing the negative charge of the cell
membrane, and regulating the cell-wall cycle [36]; ii) the
translocation of positively-charged phospholipids to the outer
membrane leaflet.
The dltABCD operon controls the D-alanylation of wall teichoic
acids in response to antimicrobial challenge, increasing the positive
charge of the cell-wall that determines a repulsion mechanism
towards positive charged molecules [4,37,38] but also indirectly
regulates the activity of the autolytic system since a decrease of the
cell-wall positive charge accelerates autolysin activity [4,39].
At the basal level, an over-expression of mprF in hVISA and dltA
in VISA, responsible for a repulsion resistance mechanism, was
found. Thus, the D-alanylation of teichoic acids is induced in
VISA, while the Lys-PG synthesis is induced in hVISA. Our
results suggest that the charge repulsion mechanism, responsible
for the poor binding of cationic antibacterials in hVISA and VISA
strains, follows two different pathways i.e. the Lys-PG synthesis in
hVISA and the D-ala teichoic acid synthesis in VISA. In addition,
the increased expression of dltA in VISA also determines a greater
amount of D-ala wall teichoic acids that could be also related with
the reduced autolysis ratio that characterizes the VISA phenotype.
This is also in agreement with the high autolysis ratio and the
absence of dltA up-regulation found in the hVISA phenotype. No
VAN and DAP inducing activity was found on dltA expression
both in Mu3 and Mu50.
As stated before, DAP but not VAN showed a modulating
activity only on mprF transcription determining an up-regulation
both in Mu3 and Mu50. Thus, Mu50 and Mu3 mprF over-
expression would result in a ‘‘drug-enhanced’’ effect in Mu3 and in
a ‘‘drug-induced’’ effect in Mu50 demonstrating that mprF is, in
some way, involved in the development of the DAP non-
susceptible phenotype.
In independent studies [23,25] different mprF point mutations,
accumulated in a specific region of the N-terminal encoding the
hydrophobic part of the junction of the Lys-PG synthase and
flippase domains [40], were repeatedly found in clinical DAP non-
susceptible isolates but it seems that the presence of such mutations
conferring a hypothetical gain in function phenotype, is not
sufficient to explain this complex phenomenon.
In fact, evaluating contrasting data reported in two different
studies, it emerges that the DAP non-susceptible strains, possessing
the S295L substitution, can present either a mprF over-expression
or its down-regulation associated with an enhanced expression of
the dlt-operon. This was also found in our results in which a down-
regulation of mprF associated with an enhanced expression of the
dlt-operon was found in Mu50, which shows a borderline DAP
MIC value of 2 mg/L and did not present the mprF mutation that
results in a change of S295L. Thus, in the VISA strain the cation
charge repulsion was due to the alalynation of teichoic acid instead
of the Lysinylation of PG. Moreover, no VAN and DAP inducing
activity was found on dltA expression.
In conclusion, hVISA and VISA exhibit common constitutive
features linked with the intermediate level of resistance i.e. an
increased cell-wall turnover, an increased positive cell-wall charge
responsible for a repulsion mechanism towards VAN and DAP,
and a reduced agr-functionality. These properties could represent
the key elements that distinguish hVISA and VISA from VSSA.
In particular, the VAN reduced susceptibility of hVISA seems to
be caused by an increased cell-wall turnover via sceDo v e r -
expression and a charge repulsion mechanism mediated by mprF
up-regulation, while it seems that VISA emerges from hVISA
only when a reduced autolysis ratio caused by a down-regulation
of major autolysin genes (atl and lytM) and a reduction of the
negative net cell envelop charge via dltA over-expression is
established (Figure 4). VAN, and more so DAP, acting with a
similar modulating mechanism both on Mu3 and Mu50, can
influence their cross-resistance mechanisms promoting Mu50
behavior in Mu3 and enhancing the cell-wall molecular
mechanisms responsible for the vancomycin intermediate resis-
tance in Mu50. DAP, in addition, can induce a charge repulsion
mechanism both in Mu3 and Mu50 acting on the mprF gene
(Figure 3, Figure 4).
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Strains
The S.aureus strains used in this study were NRS149 (VSSA),
Mu3 (hVISA), and Mu50 (VISA) kindly supplied by NARSA
(Network on Antimicrobial Resistance in Staphylococcus aureus)
(www.narsa.net), considered as prototypes and controls of VSSA,
hVISA and VISA phenotypes both in phenotypic and molecular
experiments and three clinical isolates collected in our laboratory
CZ1, SS33, and 004/210. The source and relevant characteristics
of the bacterial strains studied are listed in Table 1.
MICs and Macro Etest
MIC determination for glycopeptides and daptomycin was
performed according to Clinical and Laboratory Standards
Institute (CLSI) guidelines [41].
The Macro Etest (MET) procedure was performed growing all
clinical isolates overnight to a 2.0 McFarland standard in Mueller
Hinton broth. A 100 mL sample was plated and streaked onto BHI
agar and vancomycin and teicoplanin Etest strips were applied
(AB BIODISK, Solna, Sweden). Plates were incubated for 48 h at
37uC and were then evaluated for growth following the
manufacturer’s instructions (EAS003; AB BIODISK) [42]. Mu3
(hVISA), Mu50 (VISA) and ATCC 29213 (VSSA) were used as
control strains.
Population analysis profile/area under the curve analysis
(PAP/AUC)
The PAP/AUC procedure was performed as previously
published [42]. Briefly, colonies from cultures grown overnight
on Tryptic Soy Agar were inoculated into Tryptic Soy broth.
Following incubation for 24 h, dilutions of 10
23 (10
5 CFU/mL)
and 10
26 (10
2 CFU/mL) were prepared in saline and 50 mL were
inoculated onto BHI agar plates containing 4.0, 6.0, 8.0, 12.0 and
16.0 mg/L vancomycin and 4.0, 8.0, 16.0 and 32.0 mg/L
teicoplanin. After 48 h of incubation at 37uC, colonies were
counted and the log CFU/mL was plotted against the vancomycin
concentration using GraphPad Prism software (GraphPad Soft-
ware Inc., La Jolla, CA, USA). The ratio of AUC of the test
isolates to the AUC of S. aureus Mu3 was calculated and was
interpreted as described previously [43]. Mu3 (hVISA), Mu50
(VISA) and ATCC 29213 (VSSA) were used as control strains.
Molecular characterization
Molecular characterization of MRSA strains included in the
study was conducted by MultiLocus Sequence Typing (MLST),
Staphylococcal Cassette Chromosome mec (SCCmec) typing and
accessory gene regulator (agr) typing. All techniques were
performed as previously published [44,45].
Susceptibility to Triton X-100 autolysis
Triton X-100 autolysis was assessed as described previously [46].
Briefly, mid-logarithmic phase cultures grown in BHI were assayed
byrinsingbacterialcell pelletstwice inice-coldwaterfollowedbyre-
suspension in lysis buffer [0.05 M Tris–HCl pH 7.2, 0.05% Triton
X-100 (Sigma)]. The decrease in absorbance (A620) was monitored
at 30 min intervals for 5 h. The experiments were performed in
triplicate and the results shown as the mean 6 standard deviation of
the autolysis ratio calculated as: O.D. T0/T5.
Screening of d-hemolysin activity on 5% sheep blood
agar plates
The functionality of the agr-operon was measured by delta-
hemolysin production testing the strain by cross-streaking
perpendicularly to RN4220, which produces only b-haemolysin
[47,48,49] on a sheep blood agar (SBA) plate. This test can usually
Figure 4. Trait progression involved in the development of the different vancomycin reduced-susceptible phenotypes. Green
spot=Feature not present, Orange spot=Acquired feature or Drug induced feature, Red spot=Drug enhanced feature; Up arrow=Up-regulation,
Down arrow=Down-regulation, Dotted arrow=Trait progression, NDI=Not drug-induced.
doi:10.1371/journal.pone.0029573.g004
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b, and d–due to the interactions between them: b-haemolysin
enhances lysis by d-haemolysin, but inhibits lysis by a-haemolysin
[49]. Delta-hemolysin produced by a test strain results in a zone of
enhanced hemolysis in areas where this lysis overlaps with the
beta-hemolysin zone of RN4420.
RNA extraction, retro-transcription and quantitative real
Time RT-PCR
An aliquot of an overnight culture was diluted 1:50 and bacteria
cells were grown in BHI at the exponential phase (OD600=0.4 at
3 h) in the presence of VAN and Ca
2+-DAP, at the concentration
equal to two dilutions below the initial MIC value, or in their
absence, called ‘‘free condition’’ (F). Cells were then harvested by
centrifugation, and the bacterial pellet was stored at 280uC until
use. The cultures were re-suspended in 200 ml of diethylpyrocar-
bonate (DEPC) treated H2O, 1 ml of Trizol-reagent (GibcoBRL,
Paisley, UK) was added and incubation continued for a further
5 min. Following incubation, 200 ml of chloroform was added,
mixed by agitation; the mixture was incubated for 5 min, and
centrifuged at 10,000 g for 15 min. After centrifugation, 1 ml of
cold-isopropanol was added and the mix was maintained at
220uC for 60 min, followed by centrifugation at 12,000 g for
15 min and re-suspension of the pellet in 50 ml of DEPC-H2O and
storage at 220uC. Genomic DNA was removed by treatment with
Rnase-free-DnaseI (Ambion, Austin, TX, USA). RNA quality was
determinated by analysis of the A260/280 ratio and analysis of the
rRNA bands on agarose gels. RNA concentration was determined
spectrophotometrically. Each extracted RNA sample was also
checked for the presence of DNA contamination as a template in
the PCR assay to confirm the absence of DNA contamination.
Retro-transcription, cDNA synthesis, was carried out by using
the hexanucleotide primers ‘ImProm-II Reverse Transcriptase
Kit’ (Promega) according to the manufacturer’s instructions.
Quantitative real time RT-PCR was performed in a MX 3000P
Instrument (Stratagene) with a 2.5 ml template (cDNA), the
Brilliant SYBR Green QPCR Master mix (Stratagene), and
30 pmol of primers in a final volume of 25 ml.
PCR reaction efficiency was verified by using serial dilutions of
cDNA ranging from 10
2 to 10
6 target copies per reaction (10
4–10
8
target copies per sample, standard curve), and only oligonucleo-
tides giving PCR cycles which generate a linear fit with a slope
between 23.1 and 23.6 and amplification efficiency value (Rsq) of
90–110% were chosen. All real time RT-PCR were performed in
triplicate at an initial denaturation of 95uC for 10 min, followed by
35 cycles at 95uC for 1 min, 55uC for 1 min, 72uC for 1 min and a
final cycle at 95uC for 1 min, 55uC for 30 sec and 95uC for 30 sec.
Primers for quantification were selected to amplify a fragment of
less than 300 bp. gyrB was used as a normalizer, internal control,
as previously published [50]. All the primers used for the real time
RT-PCR study are listed in table S3.
The expression of the studied genes is represented as the
increment/decrement (fold changes) of: i) hVISA and VISA
isolates (Mu3-CZ1-SS33-Mu50-004/210) versus the VSSA isolate
(NRS149), in drug-free conditions (F) (shown as a histogram or by
fold-change values in supporting information tables); ii) each strain
in culture with VAN or DAP with respect to the drug-free
condition (shown as a histogram or by fold-change values in
supporting information tables); iii) each strain versus all the others
both in drug-free conditions and in media with the addition of
VAN and DAP (shown as a relationship of the relative amount of
transcripts of all strains in supporting information tables).
For each analysis, three to five distinct biological replicates were
carried out.
Expression analyses were performed using the relative expres-
sion software tool REST2009 (Relative Expression Software Tool).
REST applies the efficiency-corrected comparative CP method
and performs randomization tests to estimate a sample’s
expression ratio and the likelihood of up or down-regulation,
taking into account reference genes and the individual amplifica-
tion efficiency of each gene. The Excel-based relative expression
software tool, REST 2009, was applied for group wise comparison
and statistical analysis of the qPCR data as described in Pfaffl et al.
(http://rest.gene-quantification.info/). The relative expression
ratios were calculated by a mathematical model, which included
an efficiency correction for real-time PCR efficiency of the individual
transcripts, as follows: Ratio=(E target)
DCP target
(control-sample)/
(Eref)
DCP ref
(control-sample).
Therelative expression ratioofa targetgenewascomputed based
on itsrealtime PCRefficiencies (E) and the crossing point difference
(DCP) for an unknown sample versus a control. For each gene,
cDNA dilution curves were generated and used to calculate the
individual real time PCR efficiencies (E=10
[21/slope]) [51,52].
In particular, the purpose of this test was to determine whether
there was a significant difference between samples and controls,
while taking into account issues of reaction efficiency and
reference gene normalization. The test uses the hypothesis test
P(H1) that represents the probability of the alternate hypothesis
that the difference between sample and control groups is due only
to chance. The hypothesis test performs at least 2000 random
reallocations of samples and controls between the groups.
Statistical differences are significant when p,0.05.
Sequencing and sequence analysis
All amplification products were purified using the QIAquick
PCR gel extraction Kit (Qiagen) and sequenced with a LICOR
DNA 4000L sequencer. The DNA sequence was analyzed by the
gapped blast software [53].
Supporting Information
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